The aim of the present study is the retrospective evaluation of the predictive and prognostic role of HER2 expression levels in HER2+ BC patients receiving neoadjuvant treatment together with other clinico-pathologic variables as tumor infiltrating lymphocytes (TILs), histologic grade, residual tumor cellularity (RTC). The gene discussed is ERBB2; the disease is neoplasm.